Odyssean LLC Grows Stake in Adaptive Biotechnologies Corporation $ADPT

Odyssean LLC increased its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 320.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 67,709 shares of the company’s stock after purchasing an additional 51,592 shares during the period. Odyssean LLC’s holdings in Adaptive Biotechnologies were worth $1,452,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Adaptive Biotechnologies during the 2nd quarter worth approximately $324,735,000. Ameriprise Financial Inc. raised its holdings in shares of Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Adaptive Biotechnologies by 303.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after acquiring an additional 3,299,635 shares in the last quarter. Westfield Capital Management Co. LP purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter valued at approximately $65,942,000. Finally, Geode Capital Management LLC boosted its stake in shares of Adaptive Biotechnologies by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after acquiring an additional 110,825 shares during the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ADPT has been the subject of several research reports. Morgan Stanley boosted their price target on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. TD Cowen raised their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Guggenheim lifted their target price on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. BTIG Research upped their target price on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.42.

Adaptive Biotechnologies Price Performance

ADPT stock opened at $24.28 on Friday. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $26.87. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The firm has a market capitalization of $3.87 billion, a PE ratio of -59.22 and a beta of 2.09. The business has a 50 day simple moving average of $23.47 and a 200-day simple moving average of $17.96.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The company had revenue of $71.55 million for the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The business’s quarterly revenue was up 21.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.17) EPS. Equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, Director Peter M. Neupert sold 124,690 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $25.15, for a total transaction of $3,135,953.50. Following the completion of the sale, the director directly owned 130,625 shares in the company, valued at approximately $3,285,218.75. This trade represents a 48.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Francis Lo sold 51,004 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $22.45, for a total transaction of $1,145,039.80. Following the transaction, the insider directly owned 237,688 shares in the company, valued at $5,336,095.60. This trade represents a 17.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 2,011,584 shares of company stock worth $45,765,999. Corporate insiders own 5.70% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.